FindTrial
Sign In

Iparomlimab and Tuvonralimab Injection (QL1706)

DRUG6 trials

Sponsors

Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, Hebei Medical University Fourth Hospital, Wang Xin, Nanfang Hospital, Southern Medical University

Conditions

AFP Gastric or Gastroesophageal Junction AdenocarcinomaAFPGCBevacizumabCTLA-4CholangiocarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaHepatecellular Carcinoma

Phase 1

PULSAR Combined With Immunotherapy and Chemotherapy
RecruitingNCT07291947
Wang XinCholangiocarcinoma
Start: 2025-11-04End: 2027-09-10Target: 60Updated: 2025-12-18

Phase 2

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
Not yet recruitingNCT07128251
Anhui Provincial HospitalCTLA-4, Hepatocellular Carcinoma (HCC), Immunotherapy +2
Start: 2025-08-20End: 2029-12-30Target: 47Updated: 2025-08-17
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Not yet recruitingNCT07131501
The First Affiliated Hospital with Nanjing Medical UniversityCTLA-4, Hepatocellular Carcinoma, Immunotherapy +2
Start: 2025-08-11End: 2029-08-31Target: 48Updated: 2025-08-20
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
RecruitingNCT07289997
Hebei Medical University Fourth HospitalAFP Gastric or Gastroesophageal Junction Adenocarcinoma, AFPGC, Immunotherapy +1
Start: 2025-09-28End: 2028-09-30Target: 39Updated: 2025-12-17
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
RecruitingNCT07327788
Nanfang Hospital, Southern Medical UniversityBevacizumab, Hepatecellular Carcinoma, Iparomlimab and Tuvonralimab Injection +3
Start: 2025-12-25End: 2028-12-30Target: 38Updated: 2026-01-13
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
Active, not recruitingNCT07776639
Yongxu JiaGastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Start: 2026-05-10End: 2029-09-01Target: 34Updated: 2026-09-09